Extended‐release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial
Abstract
Aims: To assess the efficacy of methylphenidate as a substitution therapy for amphetamine/methamphetamine dependence in Finland and New Zealand.Design: Parallel‐group, double‐blind, randomized placebo‐controlled trial.Setting: Out‐patient care.Participants: Amphetamine‐/methamphetamine‐dependent, aged 16–65 years.Measurements: The primary outcome measure was presence/absence of amphetamine/methamphetamine in urine samples collected twice weekly. Secondary measures included treatment adherence, alterations in craving scores and self‐reported use. Primary analysis was by intention‐to‐treat (ITT). The study drug, methylphenidate (as Concerta®), was up‐titrated over 2 weeks to a maximum dose of 54 mg daily and continued for a further 20 weeks. Doses were given under daily supervision at the clinics.Findings: Seventy‐nine participants were randomized (40 methylphenidate; 39 placebo); 76 received allocated treatment and 27 completed the trial. ITT analysis (n = 78) showed no statistically significant difference in the percentage of positive urines between the methylphenidate and placebo arms (odds ratio: 0.95, 95% confidence interval: 0.83–1.08). However, there was a significant difference (P < 0.05) between the active and placebo arms in retention, the placebo arm displaying a significantly lower retention from 6 weeks that persisted until the end of the trial.Conclusions: The trial failed to replicate earlier findings suggesting that methylphenidate was superior to placebo. The low retention rate confounded the ability to draw firm conclusions about efficacy. The higher retention rate was observed in the methylphenidate arm. Any replication of this work would need to consider alternatives to the rigid clinic attendance criteria, and consider an increased dose.Keywords
Funding Information
- Niuvanniemi Hospital, Finland
- Oakley Mental Health Foundation (New Zealand)
- Waitemata District Health Board, Auckland (New Zealand)
This publication has 32 references indexed in Scilit:
- Mirtazapine to Reduce Methamphetamine UseArchives of General Psychiatry, 2011
- A Randomized, Placebo-Controlled Trial of Sustained-Release Dextroamphetamine for Treatment of Methamphetamine AddictionClinical Pharmacology & Therapeutics, 2010
- Agonist‐like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studiesAnnals of the New York Academy of Sciences, 2010
- Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependenceAddiction, 2009
- Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled TrialAmerican Journal of Psychiatry, 2008
- Impaired physical health among methamphetamine users in comparison with the general population: the role of methamphetamine dependence and opioid useDrug and Alcohol Review, 2008
- A placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawalDrug and Alcohol Review, 2008
- Single-step procedure for gas chromatography–mass spectrometry screening and quantitative determination of amphetamine-type stimulants and related drugs in blood, serum, oral fluid and urine samplesJournal of Chromatography B, 2004
- Reliability of drug dependents' self-reportsDrug and Alcohol Dependence, 1997
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987